Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mesoblast (MESO) Cash & Equivalents (2017 - 2025)

Mesoblast's Cash & Equivalents history spans 7 years, with the latest figure at $71.3 million for Q2 2023.

  • For Q2 2023, Cash & Equivalents rose 17.98% year-over-year to $71.3 million; the TTM value through Jun 2023 reached $71.3 million, up 17.98%, while the annual FY2024 figure was $63.0 million, 11.66% down from the prior year.
  • Cash & Equivalents for Q2 2023 was $71.3 million at Mesoblast, up from $60.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $136.9 million in Q2 2021 and bottomed at $50.4 million in Q2 2019.
  • The 5-year median for Cash & Equivalents is $71.3 million (2023), against an average of $89.7 million.
  • The largest annual shift saw Cash & Equivalents surged 156.47% in 2020 before it plummeted 55.84% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $50.4 million in 2019, then skyrocketed by 156.47% to $129.3 million in 2020, then increased by 5.84% to $136.9 million in 2021, then tumbled by 55.84% to $60.4 million in 2022, then rose by 17.98% to $71.3 million in 2023.
  • Per Business Quant, the three most recent readings for MESO's Cash & Equivalents are $71.3 million (Q2 2023), $60.4 million (Q2 2022), and $136.9 million (Q2 2021).